Search Results | MSF Science Portal

Journal Article

|

Review

Motta I, Boeree M, Chesov D, Dheda K, Günther G, et al.

2023-07-21 • Clinical Microbiology and Infection

BACKGROUND
Tuberculosis is a global health challenge and one of the leading causes of death worldwide. In the last decade, the tuberculosis treatment landscape has dramatically chang...

Journal Article

|

Research

Spies R, Schutz C, Ward A, Balfour A, Shey M, et al.

2022-09-27 • Southern African Journal of HIV Medicine

BACKGROUND
Patients with HIV and drug-resistant tuberculosis (TB) are at high risk of death.

OBJECTIVES
We investigated the association between rifampicin-resistant TB (...

Journal Article

|

Research

Rangaka MX, Wilkinson KA, Seldon R, van Cutsem G, Meintjes GA, et al.

2007-12-07 • American Journal of Respiratory and Critical Care Medicine

RATIONALE: Two forms of the IFN-gamma release assay (IFNGRA) to detect tuberculosis infection are available, but neither has been evaluated in comparable HIV-infected and uninfected pers...

Journal Article

|

Research

Rangaka MX, Wilkinson RJ, Boulle AM, Glynn JR, Fielding K, et al.

2014-05-14 • Lancet

Antiretroviral therapy reduces the risk of tuberculosis, but tuberculosis is more common in people with HIV than in people without HIV. We aimed to assess the effect of isoniazid prevent...

Journal Article

|

Commentary

Ariza-Vioque E, Ello F, Andriamamonjisoa H, Machault V, González-Martín J, et al.

2022-06-29 • Infectious Diseases and Therapy

Tuberculous meningitis (TBM) is the most severe and disabling form of tuberculosis (TB), with at least 100,000 cases per year and a mortality rate of up to 50% in individuals co-infected...

Journal Article

|

Research

Stucki D, Brites D, Jeljeli L, Coscolla M, Liu Q, et al.

2016-10-31 • Nature Genetics

Generalist and specialist species differ in the breadth of their ecological niches. Little is known about the niche width of obligate human pathogens. Here we analyzed a global collectio...

Journal Article

|

Research

Rangaka MX, Wilkinson RJ, Glynn JR, Boulle AM, van Cutsem G, et al.

2012-09-05 • Clinical Infectious Diseases

Current symptom screening algorithms for intensified tuberculosis case finding or prior to isoniazid preventive therapy (IPT) in patients infected with human immunodeficiency virus (HIV)...

Journal Article

|

Research

Seaman J, Boer C, Wilkinson RJ, de Jong J, de Wilde E, et al.

1995-07-01 • Clinical Infectious Diseases

An open trial of liposomal amphotericin B (AmBisome [L-AmB]; Vestar, San Dimas, CA) for treatment of complicated visceral leishmaniasis was performed in Sudan. Forty-nine patients were t...

Journal Article

|

Commentary

Zumla A, Chakaya JM, Hoelscher M, Ntoumi F, Rustomjee R, et al.

2015-07-17 • Nature Reviews Drug Discovery

Science Portal

Recent advances in the treatment of tuberculosis

Rifampicin resistance and mortality in patients hospitalised with HIV-associated tuberculosis

Effect of HIV-1 infection on T-Cell-based and skin test detection of tuberculosis infection

Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial

Capacity building in sub-Saharan Africa as part of the INTENSE-TBM project during the COVID-19 pandemic

Mycobacterium tuberculosis lineage 4 comprises globally distributed and geographically restricted sublineages

Effect of Antiretroviral Therapy on the Diagnostic Accuracy of Symptom Screening for Intensified Tuberculosis Case Finding in a South African HIV clinic

Liposomal Amphotericin B (AmBisome) in the Treatment of Complicated Kala-Azar Under Field Conditions

Towards host-directed therapies for tuberculosis